EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future

Alexey D Perenkov iD, Alena D Sergeeva, Maria V Vedunova iD, Dmitri V Krysko iD

Vaccines · 16.10.2023 · 11 (10) · 1600

DOI: 10.3390/vaccines11101600 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 16.10.2023. Verfasst von Alexey D Perenkov und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, 603022 Nizhny Novgorod, Russia. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine technology gained great impetus from the pursuit of vaccines against COVID-19. To improve the properties of RNA vaccines, and primarily their circulation time, self-amplifying mRNA and trans-amplifying mRNA were developed. A separate branch of mRNA technology is circular RNA vaccines, which were developed with the discovery of the possibility of translation on their protein matrix. Circular RNA has several advantages over mRNA vaccines and is considered a fairly promising platform, as is trans-amplifying mRNA. This review presents an overview of the mRNA platform and a critical discussion of the more modern self-amplifying mRNA, trans-amplifying mRNA, and circular RNA platforms created on its basis. Finally, the main features, advantages, and disadvantages of each of the presented mRNA platforms are discussed. This discussion will facilitate the decision-making process in selecting the most appropriate platform for creating RNA vaccines against cancer or viral diseases.

Schlagwörter

Stichwörter der Autor:innen

circular RNA vaccineimmunogenicitymRNA vaccineself-amplifying mRNA vaccinetrans-amplifying mRNA vaccinevaccine

Autor:innen und Institutionen

  • Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, 603022 Nizhny Novgorod, Russia.
  • Cell Death Investigation and Therapy (CDIT) Laboratory, Anatomy and Embryology Unit, Department of Human Structure and Repair, Faculty of Medicine and Health Science, Ghent University, 9000 Ghent, Belgium.
  • Cancer Research Institute Ghent, 9000 Ghent, Belgium.

ORCID-Profile: Alexey D Perenkov, Maria V Vedunova, Dmitri V Krysko

Förderung

  • Russian Science Foundation

Zitieren

APA

Perenkov, A. D., Sergeeva, A. D., Vedunova, M. V., & Krysko, D. V. (2023). In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future. Vaccines, 11(10), 1600. https://doi.org/10.3390/vaccines11101600

Vancouver

Perenkov AD, Sergeeva AD, Vedunova MV, Krysko DV. In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future. Vaccines. 2023;11(10):1600. doi:10.3390/vaccines11101600

BibTeX
@article{Perenkov2023,
  author = {Perenkov, Alexey D and Sergeeva, Alena D and Vedunova, Maria V and Krysko, Dmitri V},
  title = {In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {1600},
  doi = {10.3390/vaccines11101600}
}
Kostenlos starten →